Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Interest Expense : ¥-66 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Luoxin Pharmaceuticals Group Stock Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Luoxin Pharmaceuticals Group Stock Co's interest expense for the three months ended in Mar. 2024 was ¥ -15 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-66 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Luoxin Pharmaceuticals Group Stock Co's Operating Income for the three months ended in Mar. 2024 was ¥ -28 Mil. Luoxin Pharmaceuticals Group Stock Co's Interest Expense for the three months ended in Mar. 2024 was ¥ -15 Mil. Luoxin Pharmaceuticals Group Stock Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Luoxin Pharmaceuticals Group Stock Co Interest Expense Historical Data

The historical data trend for Luoxin Pharmaceuticals Group Stock Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luoxin Pharmaceuticals Group Stock Co Interest Expense Chart

Luoxin Pharmaceuticals Group Stock Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-40.08

-50.37

-105.18

-122.67

-75.97

Luoxin Pharmaceuticals Group Stock Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-24.43	-22.43	-15.36	-13.75	-14.86

Luoxin Pharmaceuticals Group Stock Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-66 Mil.

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Luoxin Pharmaceuticals Group Stock Co's Interest Expense for the three months ended in Mar. 2024 was ¥-15 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥-28 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ¥289 Mil.

Luoxin Pharmaceuticals Group Stock Co's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Luoxin Pharmaceuticals Group Stock Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luoxin Pharmaceuticals Group Stock Co Ltd (SZSE:002793) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

85 Faraday Road, Floor 1-3, Building 1, Building 2, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co Ltd is a pharmaceutical enterprise engaged in research and development, production, and trade of new drugs. It manufactures drugs for various diseases including tumor, respiratory, gastrointestinal, endocrine, cardiovascular, nervous system, antimicrobial infection, among others.

Executives

Ye Bang Mi	Supervisors
Fang Xiu Bao	Directors, executives
Zhu Fu Lin	Directors, executives
Chen Li	Supervisors
Yao Liang	Directors, executives

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Headlines

No Headlines